[go: up one dir, main page]

FR19C1053I2 - Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci - Google Patents

Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci

Info

Publication number
FR19C1053I2
FR19C1053I2 FR19C1053C FR19C1053C FR19C1053I2 FR 19C1053 I2 FR19C1053 I2 FR 19C1053I2 FR 19C1053 C FR19C1053 C FR 19C1053C FR 19C1053 C FR19C1053 C FR 19C1053C FR 19C1053 I2 FR19C1053 I2 FR 19C1053I2
Authority
FR
France
Prior art keywords
transporter
inhibitors
methods
same
sodium glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1053C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lexicon Pharmaceuticals Inc
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of FR19C1053I1 publication Critical patent/FR19C1053I1/fr
Application granted granted Critical
Publication of FR19C1053I2 publication Critical patent/FR19C1053I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR19C1053C 2006-09-29 2019-09-19 Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci Active FR19C1053I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84815606P 2006-09-29 2006-09-29
US90571407P 2007-03-08 2007-03-08
US94878007P 2007-07-10 2007-07-10
PCT/US2007/079654 WO2008042688A2 (fr) 2006-09-29 2007-09-27 Inhibiteurs de co-transporteur 2 de sodium glucose et procédés d'utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
FR19C1053I1 FR19C1053I1 (fr) 2019-11-15
FR19C1053I2 true FR19C1053I2 (fr) 2020-04-03

Family

ID=38947681

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1053C Active FR19C1053I2 (fr) 2006-09-29 2019-09-19 Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci

Country Status (24)

Country Link
US (5) US7781577B2 (fr)
EP (2) EP2308841B1 (fr)
JP (3) JP5283625B2 (fr)
KR (2) KR20150002889A (fr)
AR (1) AR063047A1 (fr)
AT (1) ATE496888T1 (fr)
AU (1) AU2007304971B2 (fr)
BR (1) BRPI0717156B8 (fr)
CA (1) CA2664688C (fr)
DE (1) DE602007012292D1 (fr)
DK (2) DK2308841T3 (fr)
EA (1) EA016511B1 (fr)
ES (1) ES2477216T3 (fr)
FR (1) FR19C1053I2 (fr)
HU (1) HUS1900038I1 (fr)
IL (1) IL197836A (fr)
MX (1) MX2009003305A (fr)
NL (1) NL301003I2 (fr)
NO (1) NO345139B1 (fr)
NZ (1) NZ575811A (fr)
PL (2) PL2308841T3 (fr)
PT (2) PT2308841E (fr)
TW (1) TWI499414B (fr)
WO (1) WO2008042688A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (fr) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012025857A1 (fr) * 2010-08-23 2012-03-01 Hetero Research Foundation Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
WO2012172566A2 (fr) * 2011-06-13 2012-12-20 Panacea Biotec Ltd. Nouveaux inhibiteurs sglt
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
RU2648467C2 (ru) 2013-02-04 2018-03-26 Тайсо Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое лекарственное средство для лечения запора
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
KR20240017116A (ko) 2013-12-17 2024-02-06 베링거잉겔하임베트메디카게엠베하 고양이과 동물에서 대사 장애의 치료
MX2016009421A (es) 2014-01-23 2016-09-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales caninos.
EP4454653A3 (fr) 2014-04-01 2025-01-22 Boehringer Ingelheim Vetmedica GmbH Traitement de troubles metaboliques chez des animaux equins
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
NZ739429A (en) 2015-08-27 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising sglt-2 inhibitors
US10626135B2 (en) * 2016-05-25 2020-04-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
CA3041169A1 (fr) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinaisons comprenant un inhibiteur de ssao/vap-1 et un inhibiteur de sglt2, leurs utilisations
ES2941108T3 (es) 2018-01-05 2023-05-16 Shandong Danhong Pharmaceutical Co Ltd Inhibidor de SGLTS y aplicación del mismo
WO2019166958A1 (fr) * 2018-02-28 2019-09-06 Mylan Laboratories Ltd Procédé pour la préparation de sotagliflozine
EP3781166A1 (fr) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Composition pharmaceutique, méthodes de traitement et utilisations associées
US20210238170A1 (en) * 2018-05-09 2021-08-05 Janssen Pharmaceutica Nv 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
PL3873600T3 (pl) 2018-10-29 2024-03-11 Boehringer Ingelheim International Gmbh Pochodne pirydynylosulfonamidu, kompozycje farmaceutyczne i ich zastosowania
US20210038627A1 (en) * 2019-03-01 2021-02-11 Lexicon Pharmaceuticals, Inc. Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
AU2020310274B2 (en) * 2019-07-05 2022-09-29 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form of SGLT inhibitor and application thereof
CA3145678C (fr) * 2019-07-26 2022-08-23 Medshine Discovery Inc. Inhibiteur de sglt2/dpp4 et son application
EP4005568B1 (fr) 2019-07-26 2024-07-10 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Inhibiteur de sglts/dpp4 et son utilisation
EP3771480A1 (fr) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Procédé continu de préparation de la forme cristalline ii de sotagliflozine
CN114727624A (zh) 2019-11-28 2022-07-08 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂在非人哺乳动物的停奶中的用途
EP4106744A1 (fr) 2020-02-17 2022-12-28 Boehringer Ingelheim Vetmedica GmbH Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez les félins
CN111763197A (zh) * 2020-07-08 2020-10-13 青岛大学 一种新型手性吲哚类化合物的合成方法
EP4376830A1 (fr) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies rénales chez des mammifères non humains
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
WO2023006745A1 (fr) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
US20240390332A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
WO2024240632A1 (fr) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Polythérapie et/ou prévention de maladies cardiaques chez des mammifères non humains comprenant un ou plusieurs inhibiteurs de sglt -2 et du pimobendane et/ou du telmisartan

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO1995016049A1 (fr) 1993-12-08 1995-06-15 The Scripps Research Institute Synthese asymetrique chimioenzymatique catalytique d'hydrates de carbone
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
JP2885191B2 (ja) 1996-07-09 1999-04-19 日本電気株式会社 液晶プロジェクタ
JP3928197B2 (ja) 1997-01-23 2007-06-13 住友化学株式会社 アリール置換芳香族類の製造方法
US6664399B1 (en) 1999-09-02 2003-12-16 E. I. Du Pont De Nemours & Company Triazole linked carbohydrates
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
BR0109323A (pt) 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
CA2429833A1 (fr) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1385856B1 (fr) 2001-04-11 2006-02-22 Bristol-Myers Squibb Company Complexes acides amines de glugocides c-aryle pour le traitement du diabete et procede correspondant
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
EP1432720A1 (fr) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation
EP1432721A4 (fr) 2001-09-13 2008-02-20 Bristol Myers Squibb Co Procede de preparation de rebeccamycine et d'analogues correspondants
FR2831169B1 (fr) 2001-10-22 2003-12-12 Servier Lab Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7521568B2 (en) 2001-12-14 2009-04-21 Purdue Research Foundation Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
US6927294B1 (en) * 2002-03-08 2005-08-09 University Of Southern California Nitrogen-containing heterocycles
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
JP3813160B2 (ja) * 2002-08-09 2006-08-23 大正製薬株式会社 アリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845995A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de pyrrolo[3,4-c]carbazole et de pyrido[2,3-b]pyrrolo[3,4-e]indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004050122A1 (fr) 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. Prevention ou traitement de maladies dues a l'hyperglycemie
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655633B2 (en) 2002-12-25 2010-02-02 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
EP1581543A4 (fr) 2003-01-03 2008-03-19 Bristol Myers Squibb Co Procedes de production d'inhibiteurs de c-aryle glucoside sglt2
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004089966A1 (fr) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. Procede de preparation selective de 5-thio-$g(b)-d-aldohexopyranoside heteroaryle
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AU2004261660A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
EP1680131A4 (fr) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv Indole- o -glucosides substitues
RS20060320A (en) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
CA2549022A1 (fr) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole-, benztriazole- et benzimidazolone-o-glucosides substitues
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
DE502004008951D1 (de) 2003-08-26 2009-03-19 Boehringer Ingelheim Pharma Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2542077A1 (fr) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Analogues de pyrovalerone et utilisations therapeutiques
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004017793A1 (de) 2004-02-21 2005-09-08 Biofrontera Discovery Gmbh Trioxacarcine und deren Verwendung
CN1922301A (zh) 2004-02-24 2007-02-28 诺和酶股份有限公司 液体去污剂中酶的稳定化
ZA200606792B (en) 2004-03-04 2007-12-27 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
AU2005225511C1 (en) 2004-03-16 2023-04-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
WO2006002233A2 (fr) 2004-06-22 2006-01-05 Wall, Michael, A. Alvaradoines e-n, nouveaux composes anthracenone g-glycosides cytotoxiques et antitumoraux
US7393836B2 (en) * 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
KR20070048188A (ko) 2004-07-08 2007-05-08 아스텔라스세이야쿠 가부시키가이샤 아줄렌 유도체의 제조방법 및 이의 합성 중간체
EP1771430A2 (fr) 2004-07-08 2007-04-11 Ciba Specialty Chemicals Holding Inc. Procede de preparation de ketones alpha-hydroxy et alpha-amine
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20080045466A1 (en) 2004-07-21 2008-02-21 Kenji Katsuno Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (fr) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
WO2006018150A1 (fr) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production
DE102004039096A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004046583A1 (de) 2004-09-23 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006037335A2 (fr) 2004-10-06 2006-04-13 Recepticon Aps Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2006050501A2 (fr) 2004-11-03 2006-05-11 University Of Kansas Analogues de novobiocine en tant qu'agents anticancereux
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
WO2006104897A2 (fr) 2005-03-25 2006-10-05 Inspire Pharmaceuticals, Inc. Composes actifs cytosquelettiques, composition et utilisation associees
US20060240496A1 (en) 2005-04-21 2006-10-26 Lakshmi Anne Immunogens, derivatives and immunoassay for ethyl glucuronide
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
US8253752B2 (en) 2006-07-20 2012-08-28 Qualcomm Incorporated Method and apparatus for encoder assisted pre-processing
EP2049524A2 (fr) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Inhibiteurs des iap
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
WO2008109591A1 (fr) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
US8015005B2 (en) 2008-02-15 2011-09-06 Motorola Mobility, Inc. Method and apparatus for voice searching for stored content using uniterm discovery
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
EP2308841B1 (fr) 2014-04-16
DK2089361T3 (da) 2011-04-18
US20080113922A1 (en) 2008-05-15
JP5701845B2 (ja) 2015-04-15
IL197836A0 (en) 2009-12-24
IL197836A (en) 2014-01-30
US20140135277A1 (en) 2014-05-15
AU2007304971A1 (en) 2008-04-10
KR20150002889A (ko) 2015-01-07
PL2089361T4 (pl) 2012-09-28
CA2664688C (fr) 2015-03-17
CA2664688A1 (fr) 2008-04-10
EA016511B1 (ru) 2012-05-30
NL301003I2 (nl) 2019-10-29
NO345139B1 (no) 2020-10-12
JP2010504998A (ja) 2010-02-18
EA200970337A1 (ru) 2009-08-28
WO2008042688A3 (fr) 2008-06-12
KR101492277B1 (ko) 2015-02-11
BRPI0717156B8 (pt) 2021-05-25
ATE496888T1 (de) 2011-02-15
US8476413B2 (en) 2013-07-02
EP2308841A2 (fr) 2011-04-13
US7781577B2 (en) 2010-08-24
PL2308841T3 (pl) 2014-09-30
NO20091700L (no) 2009-06-16
JP5283625B2 (ja) 2013-09-04
EP2089361B1 (fr) 2011-01-26
TW200826929A (en) 2008-07-01
DE602007012292D1 (de) 2011-03-10
US9365602B2 (en) 2016-06-14
TWI499414B (zh) 2015-09-11
NL301003I1 (fr) 2019-09-02
JP2013079243A (ja) 2013-05-02
US20170087172A1 (en) 2017-03-30
EP2308841A3 (fr) 2011-10-26
KR20090061072A (ko) 2009-06-15
JP2015120736A (ja) 2015-07-02
ES2477216T3 (es) 2014-07-16
DK2308841T3 (da) 2014-06-30
MX2009003305A (es) 2009-05-28
PT2089361E (pt) 2011-05-02
US20190099436A1 (en) 2019-04-04
EP2089361A2 (fr) 2009-08-19
AU2007304971B2 (en) 2013-06-20
WO2008042688A2 (fr) 2008-04-10
US20100311673A1 (en) 2010-12-09
NZ575811A (en) 2011-10-28
HUS1900038I1 (hu) 2019-09-30
PT2308841E (pt) 2014-06-11
BRPI0717156A2 (pt) 2013-10-15
DK2089361T5 (da) 2012-01-16
PL2089361T3 (pl) 2011-06-30
AR063047A1 (es) 2008-12-23
FR19C1053I1 (fr) 2019-11-15
BRPI0717156B1 (pt) 2020-06-30
JP5889453B2 (ja) 2016-03-22

Similar Documents

Publication Publication Date Title
FR19C1053I2 (fr) Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci
FR20C1033I1 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
EP1913112A4 (fr) Agent de soutenement et procedes d'utilisation
EP1855833A4 (fr) Plasmas et procedes d'utilisation
EP1943507A4 (fr) Detecteur de nox et procedes d'utilisation associes
ZA201000219B (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP2046413A4 (fr) Systèmes médicaux et leurs procédés d'utilisation
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
HK1183020A1 (zh) 鈉-葡萄糖協同轉運蛋白 的抑制劑及其用法
EP1940787A4 (fr) Nouveaux inhibiteurs de l'ido et leurs procedes d'utilisation
EP1951050A4 (fr) Compositions therapeutiques et procedes
MA28582B1 (fr) Composes de thieno-pyridinone et procedes de traitement associes
EP2030779A4 (fr) Film mince et stratifie de film mince l'utilisant
EP2066070A4 (fr) Processeur d'informations et procédé de gestion d'informations
EP1924684A4 (fr) Structure de l'état de transition de 5'-méthylthioadénosine/s-adénosylhomocystéine nucléosidases
FR2900549B1 (fr) Ensemble de conditionnement et d'application
EP1928496A4 (fr) Antagonistes de c/clp et leurs methodes d'utilisation
EP1863769A4 (fr) Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
EP1907767A4 (fr) Sytemes de pompe solaire et procedes associes
FR2905620B1 (fr) Machine-outil notamment de percage-rivetage et ses procedes de travail
EP1991058A4 (fr) Francisella atténuée et méthodes d'utilisation
EP1853727A4 (fr) Compositions de depistage de neoplasie et procedes d'utilisation
EP1978999A4 (fr) Proteine mcpip isolee et procedes d'utilisation